Clinical Trials
26 trialsNeoTHERa
University of Kansas Medical Center
EmpowHER 208
Jazz Pharmaceuticals
ctDNA in HER2+ EBC Neoadjuvant Treatment
Shanghai Jiao Tong University School of Medicine
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
University of Chicago
Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors
Oscotec Inc.
Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer (EBC)
Hebei Medical University Fourth Hospital
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI
National University Hospital, Singapore
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
ARIADNE
Karolinska University Hospital
BRE-10
University of Illinois at Chicago
Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer
Henan Cancer Hospital
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
Dana-Farber Cancer Institute
HS-10502
Jiangsu Hansoh Pharmaceutical Co., Ltd.
SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
Henan Cancer Hospital
Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.
Shanghai JMT-Bio Inc.
Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer
Henan Cancer Hospital
NEOSAMBA
Latin American Cooperative Oncology Group
The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study
The First Affiliated Hospital with Nanjing Medical University
Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
SMA-BC-002
Sun Yat-sen University
Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer
Sun Yat-sen University
Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
Shengjing Hospital
A Study for the Neoadjuvant Treatment of Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
A Study for the Adjuvant Treatment of Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer
Shengjing Hospital